Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2016 ASCO Annual Meeting /
Hypo-fractionation of prostate cancer radiotherapy

3rd - 7th Jun 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.16
Views: 2621

Dr Charles Catton - Princess Margaret Cancer Centre, Toronto, Canada

Dr Catton meets with ecancertv at ASCO 2016 to discuss the impact of hypo-fractionation of radiotherapy to treat intermediate risk prostate cancer.

In doubling the regularity of radiotherapy treatments to a 4 week course, opposed to the conventional 8 week course, Dr Catton reports no impact on patient mortality.

He discusses the manageability of intensified treatment, and how it affects patients time, toxicity and quality of life.

ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation